reducing copd exacerbations and readmissions with …€¦ · reducing copd exacerbations and...
Post on 21-Apr-2018
235 Views
Preview:
TRANSCRIPT
Reducing COPD exacerbations and readmissions with non-invasive ventilation
Home NIV for COPD
In 2012, more than one million COPD patients experienced an acute exacerbation that resulted in hospitalization.1
At $11,195 per average admission, the estimated cost to the U.S. healthcare system is more than $49 billion dollars
annually.1 Furthermore, approximately 22% of these patients are readmitted within 30 days of discharge.2 Each
hospitalization places a tremendous burden on COPD patients and their families.
In order to address these costs, Medicare has added COPD to the list of diagnoses targeted for reductions in
readmissions with a penalty of 3%. Hospitals, insurance providers, care providers and patients are looking for better
solutions for the long-term care of COPD patients.3
ResMed.com/NIVforCOPD
Compliance Report
30 day compliance 06/10/2011 - 07/09/2011
Compliance met Yes
Compliance percentage 86%
Usage 06/10/2011 - 07/09/2011
Usage days 28/30 days (93%)
>= 4 hours 26 days (86%)
< 4 hours 2 days (7%)
Usage hours 174 hours 42 minutes
Average usage (total days) 5 hours 49 minutes
Average usage (days used) 6 hours 14 minutes
Median usage (days used) 6 hours 24 minutes
S9 AutoSetSerial number 42102071722
Mode AutoSet
Min Pressure 4.0 cm H O
Max Pressure 20 cm H O
EPR Off
EPR Level 0
TherapyPressure - cm H O Median: 9.7 95th percentile: 12.0 Maximum: 13.5
Leaks - L/min Median: 0.0 95th percentile: 2.4 Maximum: 12.6
Events per hour AI: 0.6 HI: 0.2 AHI: 0.8
Apnea Index Central: 0.0 Obstructive: 0.6 Unknown: 0.0
Usage - Hours
Abshire, Odessa06/10/2011 - 07/09/2011ID: 04806065DOB: 06/05/1975Age: 36 yearsGender: Female
Sleep Distributor LLC NU942 High FreewaySouthmouthNunavut,68841
Printed on 4/25/2012 - ResMed EasyCare Online version 1.2 Page 1 of 1
Phone: (500)071-7534 x58271Fax: 660-726-4829 x9795Email: admin@sleepdistributorllcnu.com
10 12 14 16 18 20 22 24 26 28 30 2 4 6 8 10
1614121086420
2
2
2
Sun Sun Sun Sun Sun
Printed on 5/25/2012 - ResMed EasyCare Online version 1.2
THERAPY REPORT
Printed on 5/25/2012 - ResMed EasyCare Online version 1.2
USAGE AND COMPLIANCE REPORT
Why NIV for COPD?If COPD sufferers are admitted to the hospital due to an acute exacerbation, they are often placed on non-invasive
ventilation (NIV.) However, once they are discharged, they continue with their standard therapy of pharmacology
and/or oxygen. Oxygen therapy addresses hypoxemia caused by impaired gas exchange in the lung tissue (type
1 respiratory failure); however, unlike NIV, it does not address hypercapnia caused by ventilatory failure (type 2
respiratory failure). By adding NIV to your standard care regimen, you may be able to effectively treat both types
of respiratory failure in your COPD patients.
Research shows that the use of NIV at home:
• Reduces mortality in patients with COPD by 76%4
• Reduces admissions and minimizes costs for hospitals5
• Reduces recurrence of acute hypercapnic respiratory failure following an initial event by 60.2% in the first
30 days following the event when compared to CPAP (38.5%)6
• May lead to an improved quality of life7, 8
Despite clinical evidence that NIV may improve health outcomes associated with COPD,
NIV is still not often considered for chronic care.
Data monitoring for successful patient follow-up Due to the likelihood of rehospitalization following an acute
exacerbation, it’s important for care providers to monitor and
provide follow-up care for COPD patients post-discharge.
In fact, research shows that monitoring the breathing rate of
hypercapnic COPD patients in home allows early identification
of COPD exacerbations.9
With AirView™, ResMed’s cloud-based data management
system, you can view critical ventilation data and key metrics
such as respiratory rate and minute ventilation to
determine if patients are in distress or
at an increased risk for an acute
exacerbation – particularly
in the critical 30 days
post-hospital discharge.
Patient identity and corresponding data used are fictional.
ResMed’s NIV therapy solutionsOur home NIV solutions are focused on helping reduce acute exacerbations of COPD and hospital readmissions.
With our sophisticated range of comfortable, effective therapy and tools, we can guide you in the long-term
management and ventilation care of your COPD patients.
With our sophisticated NIV technologies, you can be confident that your patients are receiving comfortable, effective and synchronized treatment from their ResMed device.
Improved O2 delivery and ventilation monitoringIntegrated FiO2 monitoring in Astral 150 allows you to prescribe concentrations (e.g.FiO2) of oxygen, which are more precise than liter flows (e.g. LPM), in addition to the option of integrated oximetry for objective patient monitoring.
iVAPS: Unlike other ventilation modes that only target tidal volume, iVAPS targets a unique minute ventilation algorithm, which accounts for anatomical dead space, to ventilate patients more effectively.
TiControl™: For patients who experience challenges in exhaling, a shortened Ti Max (maximum time spent in inspiration) will allow for longer exhalation time and may provide better comfort and less likelihood of air trapping or intrinsic PEEP.
Trigger/cycle sensitivity: Adjustable trigger and cycle sensitivities allow further customization at the beginning and end of each inspiration, which further improves patient-device synchronization.
AirCurve™ 10 ST-A
Our premium homecare device is optimized to treat COPD using the latest volume-
assured pressure support technology, iVAPS.™ This technology responds to respiratory
rate, targets alveolar ventilation and automatically adjusts pressure support as
needed to accommodate the patient’s needs, even as their disease progresses.
Astral™ 100/150
For more advanced clinical needs, our Astral life support ventilator offers a broad
range of therapy modes and features to optimize the treatment of your COPD
patients. With unique synchrony features that maximize expiratory time and
integrated FiO2 monitoring in Astral 150 that lets you fine-tune oxygen delivery, Astral
offers the quality of life benefits that are so important to chronically ill COPD patients.
AirView
AirView, our cloud-based data management system, is available for both Astral
and AirCurve 10 ST-A devices. AirView can help both physicians and home medical
equipment providers (HMEs) by providing daily access to key patient data,
enabling efficient collaboration and coordinated patient care.
• Access key ventilation parameters, such as usage, AHI, tidal volume,
minute ventilation and respiratory rate
• Allows for early patient intervention before a potential problem or
hospitalization occurs
• Provides consistent care for COPD patients by standardizing routine
home monitoring
Patient identity and corresponding data used are fictional.Distributed by ResMed Corp, 9001 Spectrum Center Boulevard, San Diego, CA 92123 USA +1 858 836 5000 or 1 800 424 0737 (toll free). See ResMed.com for other ResMed locations worldwide. AirCurve, AirView, Astral, iVAPS and TiControl are trademarks and/or registered trademarks of the ResMed family of companies. Specifications may change without notice. © 2017 ResMed. 1019069/4 2017-02
Just like you, our goal is to help COPD patients enjoy a better quality of life. Visit ResMed.com/NIVforCOPD to learn how implementing a home NIV program can help you manage your patients’ treatment so they can get the most out of each day.
1 Perera PN et al. Acute exacerbations of COPD in the United States: inpatient burden and predictors of cost and mortality. COPD 2012;9:131– 44.2 Jencks S F et al. Rehospitalizations among patients in the Medicare fee-for-service program. New Engl J Med 2009;360(14): 1418-28. 3 Boutwell A. Time to get serious about hospital readmissions. Health Affairs Blog, October 12, 2012.
http://healthaffairs.org/blog/2012/10/10/time-to-get-serious-about-hospital-readmissions (accessed November20, 2014).4 Köhnlein T et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised,
controlled clinical trial. Lancet Respir Med 2014 Sep;2(9):698-705.5 Tuggey JM, Plant PK and Elliott MW. Domiciliary non-invasive ventilation for recurrent acidotic exacerbations of COPD: An economic analysis. Thorax 2003;58(10):867–71.6 Cheung AP et al. A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. Int J Tuberc Lung Dis 2010;14:642–9.7 Tsolaki et al. One-year non-invasive ventilation in chronic hypercapnic COPD: Effect on quality of life. Respir Med 2008;102(6):904–11.8 Duiverman ML et al. Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. Thorax 2008;63(12):1052–7.9. Yanez et al. Monitoring breathing rate at home allows early identification of COPD exacerbations. Chest 2012; 142 (6): 1524-9
ResMed.com/NIVforCOPD
top related